Eylea Reaches 2,000 Patients Since Bayer-Santen Japan Launch
This article was originally published in PharmAsia News
Approximately 2,000 patients have used vascular endothelial growth factor inhibitor Eylea (aflibercept), a drug for the treatment of exudative age-related macular degeneration, after the product was launched by Bayer Pharmaceuticals and Santen Pharmaceuticals just over a month ago on Nov. 27, 2012.
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.